Study of Spermatogenesis Suppression With DMAU Alone or With LNG Versus Placebo Alone in Normal Men
Status:
Unknown status
Trial end date:
2020-06-01
Target enrollment:
Participant gender:
Summary
This is a Phase IIa multicenter, double-blind, placebo-controlled study in healthy men to
evaluate the spermatogenesis suppression after oral administration of Dimethandrolone
Undecanoate (DMAU) alone or with Levonorgestrel (LNG) for 12 weeks versus placebo alone.
Phase:
Phase 2
Details
Lead Sponsor:
Health Decisions
Collaborators:
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Los Angeles Biomedical Research Institute Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center University of Washington